Matilla José-María, Zabaleta M, Martínez-Téllez E, Abal J, Rodríguez-Fuster A, Hernández-Hernández J
Department of Thoracic Surgery, University Hospital of Valladolid, Valladolid, Spain.
Department of Pneumonology, Valdecilla University Hospital, Santander, Spain.
J Clin Transl Res. 2020 Sep 2;6(4):145-154. eCollection 2020 Oct 29.
Carrying out a correct anatomical classification of lung cancer is crucial to take clinical and therapeutic decisions in each patient.
TNM staging classification provides an accurate anatomical description about the extension of the disease; however, the anatomical burden of the disease is just one aspect that changes the prognosis.
TNM staging classification is a tool that predicts survival, but we must consider that TNM is just one of the factors that concern the prognosis. The impact of a factor over the prognosis is complex due to: It depends on the specific environment, the treatment strategy, among others, and our level of certainty makes difficult to include all the factors just in a group of stages. In some groups, there are difficulties to get large series due to the low frequency of cases and the small number of events (metastasis, locoregional recurrence). It does not allow to obtain evidence in a short period of time. On the other hand, in the next years, new markers will be incorporated in the coming years, which are going to be included in the new TNM classification. It could help to improve the classification giving more information about prognosis and risk of recurrence. All these aspects are being used by the International Association for the Study of Lung Cancer (IASLC) to develop a new prognosis model. This continues the evolution of TNM system, allows us to overcome the difficulties, and build a flexible framework enough to continue improving the individual prognosis of the patients.
对肺癌进行正确的解剖学分类对于为每位患者做出临床和治疗决策至关重要。
TNM分期分类提供了关于疾病扩展的准确解剖学描述;然而,疾病的解剖学负担只是影响预后的一个方面。
TNM分期分类是一种预测生存的工具,但我们必须认识到TNM只是影响预后的因素之一。一个因素对预后的影响很复杂,原因如下:它取决于特定环境、治疗策略等,而且我们的确定性水平使得难以仅在一组分期中纳入所有因素。在某些组中,由于病例频率低和事件数量少(转移、局部区域复发),难以获得大量病例系列。它无法在短时间内获得证据。另一方面,在未来几年,新的标志物将被纳入新的TNM分类中。这可能有助于改进分类,提供更多关于预后和复发风险的信息。国际肺癌研究协会(IASLC)正在利用所有这些方面来开发一种新的预后模型。这延续了TNM系统的发展,使我们能够克服困难,并构建一个足够灵活的框架以持续改善患者的个体预后。